Text Size

Relationship Between Macular Thickness Measurement and Signal Strength in Optical Coherence Tomography

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Meir Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Meir Medical Center
ClinicalTrials.gov Identifier:
NCT01115881
First received: May 2, 2010
Last updated: May 3, 2010
Last verified: January 2010
History of Changes
  Purpose

Signal strength is a parameter introduced in analysis software version 4.0.1, of the OCT stratus, that combines SNR and uniformity of the signal within a scan The scale of signal strength ranges from 1 to 10, with 1 representing poor image quality and 10 representing excellent image quality It has been showed that signal strength has a better image quality discriminating ability than SNR The operation manual recommends a minimum signal strength of 5 for macular thickness measurement There is no consensus on the level of signal strength above which should be considered to be good quality The inclusion Criteria for acceptable signal strength varies widely in the literature the purpose of our study is to examine the relationship between signal strength and macular thickness measured by stratus OCT


Condition
Optical Tomography

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Further study details as provided by Meir Medical Center:

Estimated Enrollment: 40
Study Start Date: May 2010
Estimated Study Completion Date: November 2010
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

healthy

Criteria

Inclusion Criteria:

  • healthy subjects in this study other than refractive error, all included eyes had no concurrent ocular pathologic features BCVA of at least 20/30, and had spherical refractive error within the range of
  • 4.00 D to 4.00 D

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01115881

Contacts
Contact: Ori Segal, M.D 972-522-730227 orisegal@netvision.net.il

Locations
Israel
Meir medical center Not yet recruiting
Kfar-Saba, Israel
Contact: Ori Segal            
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Ori Segal, M.D Sackler school of medicine Tel-Aviv university
  More Information

No publications provided

Responsible Party: Ori Segal, Meir Medical Center
ClinicalTrials.gov Identifier: NCT01115881     History of Changes
Other Study ID Numbers: OCT-1
Study First Received: May 2, 2010
Last Updated: May 3, 2010
Health Authority: Israel: Ethics Commission

Keywords provided by Meir Medical Center:
To examine the relationship between signal strength and macular thickness measured by stratus OCT

ClinicalTrials.gov processed this record on May 22, 2013